Stories about Molecule

Subscribe to Molecule

08.12.2020 – 15:15

Gerresheimer AG
Gerresheimer: On the path to sustainable profitable growth

Duesseldorf (ots) - - Transformation into a growth value as innovation leader and solution provider - Gerresheimer presents strategy process formula G as an engine towards sustainable profitable growth - Over proportional growth will be achieved by expanding in high value solutions, digital applications and growth regions - Strategic investments in growth ...
One document
more
05.12.2020 – 16:00

Sysmex Inostics GmbH
Sysmex Inostics Presents Data at the American Society of Hematology Annual Meeting Demonstrating Exquisite Sensitivity of SafeSEQ NGS Technology for Detection of Measurable Residual Disease in Acute Myeloid Leukemia

Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based, high-sensitivity molecular testing for oncology, is presenting the poster "Ultrasensitive Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML) Using a Targeted Next Generation Sequencing (NGS) Panel" at ...

more
02.12.2020 – 13:00

BD (Becton, Dickinson and Company)
BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years

Franklin Lakes, N.j. (ots/PRNewswire) - - Investment includes new manufacturing facility in Europe BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and ...

more
01.12.2020 – 06:46

Institute for Advanced Sustainability Studies e.V. (IASS)
Hydrogen-Powered Heavy Duty Vehicles Could Contribute Significantly To Achieving Climate Goals

Press release Hydrogen-Powered Heavy Duty Vehicles Could Contribute Significantly To Achieving Climate Goals A partial transition of German road transport to hydrogen energy is among the possibilities being discussed to help meet national climate targets. A team of researchers from the Institute for Advanced ...

more
23.11.2020 – 12:55

Fördergesellschaft IZB mbH

5
Commemorative publication for the 25th anniversary of the IZB presents 70 profiles and visions of successful biotech start-ups

In the IZB you can find over 50 biotech start-ups
One document
more
17.11.2020 – 12:00

Technische Universität München
Metal-organic frameworks become flexible: Combined efforts of experiment and simulation pave the way to new applications

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36313/ High resolution images: https://mediatum.ub.tum.de/1579159 NEWS RELEASE Metal-organic ...

more
17.11.2020 – 08:58

Stada Arzneimittel
STADA and PharmaMar sign agreement to commercialize Yondelis® (trabectedin) in the MENA region

Press Release STADA and PharmaMar sign agreement to commercialize Yondelis® (trabectedin) in the MENA region - PharmaMar has granted to STADA a license to market the Yondelis® (trabectedin) marine-derived cancer treatment in 15 Middle East-North Africa countries. - According to Luis Mora, Managing ...
One document
more
11.11.2020 – 12:26

Technische Universität München
Climate-adapted plant breeding: Improvement of crops with seeds from gene banks

Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36306/ Images for journalists: https://mediatum.ub.tum.de/1578802 NEWS RELEASE Improvement of crops with seeds from gene banks Climate-adapted plant breeding Securing plant production is a ...

more
09.11.2020 – 14:07

Merck KGaA
Merck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics

Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Merck out-licenses Phase IIb-ready atacicept to Vera Therapeutics - Phase IIa trial conducted by Merck shows promising results in IgA nephropathy (IgAN), also known as "Berger's disease" - Out-licencing deal includes 10% equity in Vera Therapeutics and up to EUR 605 million in development ...

more
05.11.2020 – 16:06

Novo Nordisk A/S
Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy

Bagsværd, Denmark (ots/PRNewswire) - Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural therapy (IBT) demonstrated significantly more body weight loss compared to placebo plus IBT.[i] The STEP 3 phase 3a trial investigated ...

more
03.11.2020 – 10:49

nova-Institut GmbH

2
PRESS RELEASE: Renewable Carbon Initiative (RCI) supports the European Green Deal, but calls for an extension to the material sector through a comprehensive renewable carbon strategy

Keep in touch

more
02.11.2020 – 14:21

Technische Universität München
Immune response: memory T cells are formed earlier than previously thought

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22562 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36297/ NEWS RELEASE How the immune system remembers viruses Immune response: memory T cells are formed earlier than previously thought For a person to ...

more
02.11.2020 – 09:00

EvoBiotiX
EvoBiotiX collaborates with Boehringer Ingelheim and the University of Salzburg on naturally derived Extracellular Vesicles (EVs)

Salzburg/Melide(CH) (ots) - Swiss Biotech EvoBiotiX SA today announced a multi-year collaboration with Boehringer Ingelheim in the field of naturally derived EVs. A significant part of this program will fund research of the drug delivery potential of naturally derived EVs in the group of Prof. Meisner-Kober at the ...

more
29.10.2020 – 11:29

Technische Universität München
Smart bottle brushes: Neutrons make structural changes in molecular brushes visible

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36275/ High resolution images: https://mediatum.ub.tum.de/1577653 NEWS RELEASE Smart bottle brushes Neutrons make structural changes in molecular brushes ...

more
20.10.2020 – 16:39

Technische Universität München
Coronavirus: door opener facilates cell entry

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22562 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36263/ NEWS RELEASE How the virus enters the cell Coronavirus: Neuropilin-1 could open the door to the inside of the cell The protein neuropilin-1 facilitates SARS CoV-2 cell entry. A research team including ...

more
15.10.2020 – 11:27

Technische Universität München
Fighting corona with machine learning

Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36254/ NEWS RELEASE The Bavarian Research Foundation is funding five TUM-research projects on Covid-19 Fighting corona with machine learning The Technical University of Munich (TUM) is starting five new research projects that focus on the ...

more
14.10.2020 – 12:30

Technische Universität München
An alternative to animal experiments - New applications for organoids from human intestinal tissue

Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36252/ Images for journalists: https://mediatum.ub.tum.de/1576619 NEWS RELEASE New applications for organoids from human intestinal ...

more
06.10.2020 – 14:00

Merck KGaA
Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis

Darmstadt, Germany (ots/PRNewswire) - - Merck out-licenses promising clinical-stage program to Novartis - Anti-ADAMTS5 Nanobody® programis Phase II-ready with novel MoA which could protect against cartilage damage and reduce joint pain - Merck receives upfront payment of EUR 50 million with the potential of ...

more
30.09.2020 – 14:30

nova-Institut GmbH

2
PRESS RELEASE (DE/EN): The future of the chemical and plastics industry: Renewable Carbon

Keep in touch

more
29.09.2020 – 14:55

Technische Universität München
Intelligent software for a better understanding of plant tissue development

Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36238/ Images for journalists: https://mediatum.ub.tum.de/1575701 NEWS RELEASE Intelligent software for a better understanding of plant tissue development 3D images display plant organs down ...

more
23.09.2020 – 14:23

nova-Institut GmbH

3
PRESS RELEASE:

Keep in touch

more
22.09.2020 – 11:00

Debiopharm International SA
DEBIOPHARM HONORED AS A 2020 SWISS BIOTECH SUCCESS STORY WINNER FOR OUTSTANDING ACHIEVEMENTS OVER 40 YEARS

Lausanne, Switzerland (ots) - Debiopharm, (www.debiopharm.com), a Swiss-based biopharmaceutical company today announced being one of the recipients of the 2020 Swiss Biotech Success Story Award for exceptional achievements in the biotech industry. Every year, the Swiss Biotech Association awards companies or ...

more
02.09.2020 – 14:13

Technische Universität München
Finding cortisone alternatives with fewer side effects

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/die-tum/aktuelles/pressemitteilungen/details/36207/ Images for journalists: https://mediatum.ub.tum.de/1559845 NEWS RELEASE DNA binding is essential for effectiveness of steroids Finding cortisone alternatives with fewer side effects Many people use ...

more
20.08.2020 – 16:21

Jennewein Biotechnologie GmbH
US Customs rules in favor of Jennewein Biotechnologie regarding importation of 2'-Fucosyllactose

RHEINBREITBACH, Germany (ots) - Jennewein Biotechnologie GmbH the leading manufacturer of human milk oligosaccharides (HMOs) in the world, announced today that the Intellectual Property Rights Branch, Regulations and Rulings, U.S. Customs and Border Protection issued a Ruling Letter which asserts that the HMO 2'-fucosyllactose (2'-FL) being produced by Jennewein ...

more
17.08.2020 – 16:38

Fördergesellschaft IZB mbH

KOPIE VON: Inspirational talks form SIRION Biotech, CLS Behring and the German Accelerator at the 13th Biotech Press Lounge at the IZB

In the IZB you can find over 50 biotech start-ups
One document
more
17.08.2020 – 11:26

Technische Universität München
Designed bacteria produce coral-antibiotic

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36204/ High resolution images: https://mediatum.ub.tum.de/1554685 NEWS RELEASE Sustainable biotechnological production of a natural substance against tuberculosis Designed bacteria produce coral-antibiotic Corals growing on the reefs of ...

more
29.07.2020 – 15:00

Jennewein Biotechnologie GmbH
Jennewein Biotechnologie GmbH announces the foundation of Jennewein Biotech Corp. USA

Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH, a market leading and science-based company for developing and producing human milk oligosaccharides (HMOs) and rare monosaccharides, announced today that it has established its subsidiary in the USA. Jennewein Biotech USA Corporation, a Delaware Corporation, utilizing warehouses in Chicago, IL and Columbus, OH, will ...

more
29.07.2020 – 07:00

UCB Pharma
UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease

Brussels (ots/PRNewswire) - - UCB to provide to Roche and Genentech exclusive, world-wide license to UCB's UCB0107, an innovative anti-Tau antibody treatment - UCB will receive an initial upfront payment and, after positive completion of proof-of-concept in Alzheimer's Disease, is eligible to receive further ...

more
27.07.2020 – 07:10

UCB Pharma
UCB Half Year Report 2020

Brussels (ots/PRNewswire) - - UCB's resilient product portfolio drives continued company growth - Revenue increased to EUR 2.6 billion and net sales to EUR 2.5 billion, both +12%, +9% CER or +10% at CER and adjusted for divestitures respectively - Underlying profitability (adj. EBITDA) was EUR 783 million (+8%, 0% CER) or a ratio of 30% - Ra Pharma acquisition closed early April, Engage Therapeutics acquired in June, co-promotion agreement for Cimzia® with Ferring in July - ...

more
23.07.2020 – 15:02

Norgine; AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals and Norgine B.V. Enter Into Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New Zealand

Waltham, Mass. and Amsterdam (ots/PRNewswire) - Agreement provides AMAG with $30 million upfront payment and eligibility to receive up to $260 million in development and commercial milestones in addition to sales royalties Collaboration further advances the development of ciraparantag AMAG Pharmaceuticals, Inc. ...

more

12345Next